|Bid||7.06 x 1000|
|Ask||7.07 x 1400|
|Day's Range||6.81 - 7.20|
|52 Week Range||2.27 - 8.08|
|PE Ratio (TTM)||N/A|
|Earnings Date||Nov 12, 2018 - Nov 16, 2018|
|Forward Dividend & Yield||N/A (N/A)|
|1y Target Est||12.50|
Is Amyris significantly overestimating the royalty revenue it's owed? If so, that could really hurt shareholders down the road.
Amyris, Inc. (AMRS) (“Amyris” or the “Company”), a leader in the development and production of sustainable ingredients for the Health & Wellness, Clean Beauty and Flavors & Fragrances markets, today announced the pricing of the previously announced underwritten secondary offering of approximately 7.65 million shares by certain of its existing stockholders (the “selling stockholders”) at the public offering price of $6.25 per share. No shares are being sold by the Company. In connection with the offering, the selling stockholders are exercising warrants for approximately 10.5 million shares of common stock, which is expected to result in gross cash proceeds to Amyris of approximately $46 million, assuming full exercise of the underwriter’s option.
Amyris, Inc. (AMRS) (“Amyris” or the “Company”), a leader in the development and production of sustainable ingredients for the Health & Wellness, Clean Beauty and Flavors & Fragrances markets, today announced that certain of its existing stockholders (the “selling stockholders”) intend to offer up to approximately 7.4 million shares of the Company’s common stock in an underwritten secondary offering. In addition, one of the selling stockholders intends to grant the underwriter a 30-day option to purchase up to an additional 15% of the shares offered in the secondary offering.
Q2 2018 GAAP revenue of $24.8 million, compared with GAAP revenue of $25.7 million for Q2 2017. Second-quarter revenue of $24.8 million compared with the same period in 2017 of $21.7 million when adjusted ...
NEW YORK, NY / ACCESSWIRE / August 6, 2018 / Amyris, Inc. (NASDAQ: AMRS ) will be discussing their earnings results in their Q2 Earnings Call to be held on August 6, 2018 at 4:30 PM Eastern Time. To listen ...
Amyris, Inc. (AMRS), the industrial bioscience company, today announced that it plans to participate in the following upcoming investor conference in August 2018. Amyris will provide an update on its business during the presentation. A live webcast of the presentation including slides and a replay will be available on the investor relations section of the company's website at http://investors.amyris.com. Amyris is the integrated renewable products company that is enabling the world’s leading brands to achieve sustainable growth.
Biossance™, the high growth clean beauty brand from Amyris, Inc. (NASDAQ:AMRS), today announced that it has executed an agreement with Sephora to launch the brand across all 668 of Sephora’s Inside JCPenney locations beginning in September 2018. Driven by consumer demand for leading clean beauty products, the Biossance brand’s rapid expansion has continued in the U.S., Canada and recently in Brazil, by providing No Compromise Beauty™ non-toxic products that perform. This expansion in the number of retail locations supporting clean beauty and making Biossance available to consumers is a critical component of delivering over 300% sales growth for Biossance that Amyris expects for 2018.
In support of its growth strategy to become a global leader in Clean Beauty, Amyris (AMRS) has announced two executive appointments to ensure it can respond quickly to the surging consumer demand for its Clean Beauty skincare products from Biossance™, now the fastest selling skincare brand in North America. Caroline Hadfield has been promoted to President of Biossance, and is recognized for leading its launch and subsequent success with consumers looking for clean, non-toxic skincare that delivers superior performance. Formerly Senior Vice President of Personal Care at Amyris, Ms. Hadfield will continue to lead brand positioning, new product and category innovation and development, supply chain management and operations. A leading advocate for the introduction of Clean Beauty in the skincare market, she has successfully established Biossance as a leader in this rapidly growing sector of the market, delivering an outstanding range of Clean Beauty products that meet our No Compromise™ philosophy of safe, non-toxic ingredients that are efficacious and deliver superior performance.
LONDON, UK / ACCESSWIRE / July 11, 2018 / If you want a free Stock Review on AXTA sign up now at www.wallstequities.com/registration. WallStEquities.com has selected the following stocks for review: Aemetis Inc. (NASDAQ: AMTX), Amyris Inc. (NASDAQ: AMRS), Axalta Coating Systems Ltd (NYSE: AXTA), and Ecolab Inc. (NYSE: ECL).
Amyris, Inc. (AMRS), a leader in the development and production of sustainable ingredients for the Health & Wellness, Clean Beauty and Flavors & Fragrances markets, announces that it has closed on a $36 million term loan with Great American Capital Partners, LLC ("GACP"), a subsidiary of B. Riley Capital Management, LLC, an SEC Registered Investment Advisor and wholly-owned subsidiary of B. Riley Financial, Inc. Cash from the term loan will be used to pay off the company’s Stegodon and other short-term debt maturities. The term loan also includes an additional $35 million accordion credit facility that provides Amyris with another option for financing construction of its production facility, if necessary.
Amyris is disrupting markets by using the most advanced science and technology, including machine-learning and robotics to program yeast to create targeted molecules, at a lower cost and with sustainable supplies, resulting in sustainable methods of materials production. Amyris is the only company in the sector that has production capability at industrial scale, is evidenced by its clean manufacturing and commercialization of 15 products and its established supply agreements with market leaders across a range of business segments. Amyris is now expanding its production contract with ADL in order to provide additional, cost-effective manufacturing capability to meet the higher than expected demands from its partners.
Amyris, Inc. (AMRS), a leader in the development and production of sustainable, fermentation-derived ingredients in the markets of Health & Wellness, Clean Beauty and Flavors & Fragrances announces that it plans to partner with BGI, the world’s largest genomics company. The companies intend to apply their synthetic biology platforms in a new joint venture to discover, develop and commercialize human microbiome-targeting health and nutrition products in Greater China. The joint venture seeks to combine Amyris’s best-in-class science and technology with BGI’s gene sequencing expertise, data and analytics.
Amyris, Inc. (AMRS), the industrial bioscience company, today announced that it has executed an agreement for a significant project consortium in Europe with the Universidade Católica Portuguesa (UCP) Porto Campus and AICEP Portugal Global (AICEP). UCP is a university system, including the leading biotech school in Portugal, and operates 15 research centers. AICEP is an independent public entity of the Government of Portugal, focused in encouraging the best foreign companies to invest in Portugal.
Amyris, Inc. (AMRS), the industrial bioscience company, today announced that it is set to join the Russell Microcap® Index at the conclusion of the Russell US Indexes annual reconstitution, effective after the US market opens on June 25, according to a preliminary list of additions posted June 8. Membership in the Russell Microcap® Index, which remains in place for one year, means automatic inclusion in the appropriate growth and value style indexes. FTSE Russell determines membership for its Russell US Indexes primarily by objective, market-capitalization rankings and style attributes.
Amyris (AMRS) is one stock you should avoid as it has seen a significant price decline and is also seeing negative earnings estimate revisions.
LONDON, UK / ACCESSWIRE / May 31, 2018 / If you want a free Stock Review on AXTA sign up now at www.wallstequities.com/registration. Lined up for evaluation this morning are these four stocks: Aemetis Inc. (NASDAQ: AMTX), Amyris Inc. (NASDAQ: AMRS), Axalta Coating Systems Ltd (NYSE: AXTA), and Ecolab Inc. (NYSE: ECL).
LONDON, UK / ACCESSWIRE / May 23, 2018 / If you want access to our free earnings report on LyondellBasell Industries N.V. (NYSE: LYB) ("LyondellBasell"), all you need to do is sign up now by clicking the following link www.active-investors.com/registration-sg/?symbol=LYB. LyondellBasell posted its financial results for first quarter of fiscal year 2018 (Q1 FY18) on April 27, 2018. The multinational chemical Company surpassed analysts' estimates for revenue and earnings for Q1 FY18.
LONDON, UK / ACCESSWIRE / May 22, 2018 / If you want access to our free research report on Amyris, Inc. (NASDAQ: AMRS), all you need to do is sign up now by clicking the following link www.active-investors.com/registration-sg/?symbol=AMRS as the Company's latest news hit the wire. On May 18, 2018, the Company, which is an industrial bioscience organization, and Chevron Products Co. ("Chevron"), a division of Chevron U.S.A. Inc. (NYSE: CVX), together declared that Amyris' sustainable lubricants joint venture JV Company, Novvi, has entered into an agreement with Chevron to jointly develop and bring to market novel renewable base oil technologies.
NEW YORK, May 17, 2018 /PRNewswire/ -- Biossance™, the consumer beauty brand from Amyris, Inc. (AMRS), continues to lead the clean beauty movement with the launch of its new decked-out Clean Beauty Bus, bringing clean skincare products to a wider audience of consumers seeking non-toxic products that meet their needs.